Table 1.
Exposure | Outcome | n SNPs | IVW Odds Ratio (95% CI) | IVW p-Value 1 | Cochrane’s Q | Cochrane’s Q p-Value 1 | MR-Egger Intercept | MR-Egger Intercept p-Value 1 |
---|---|---|---|---|---|---|---|---|
Zn | SARS-CoV-2 infection | 2 | 0.97 (0.87–1.08) | 0.548 | 0.73 | 0.394 | NA 2 | NA 2 |
Zn | Hospitalized (ver. non-hospitalized) | 2 | 0.99 (0.69–1.44) | 0.971 | 0.02 | 0.889 | NA 2 | NA 2 |
Zn | Hospitalized (ver. population) | 2 | 1.06 (0.81–1.39) | 0.663 | 1.62 | 0.203 | NA 2 | NA 2 |
Zn | Very severe COVID-19 | 2 | 1.21 (0.79–1.86) | 0.386 | 2.09 | 0.148 | NA 2 | NA 2 |
Zn subsignificant | SARS-CoV-2 infection | 12 | 1.01 (0.98–1.05) | 0.489 | 7.32 | 0.772 | 0.898 | 0.468 |
Zn subsignificant | Hospitalized (ver. non-hospitalized) | 12 | 0.97 (0.85–1.11) | 0.688 | 14.09 | 0.228 | 0.717 | 0.496 |
Zn subsignificant | Hospitalized (ver. population) | 12 | 0.98 (0.91–1.06) | 0.623 | 13.40 | 0.268 | 0.108 | 0.424 |
Zn subsignificant | Very severe COVID-19 | 12 | 0.92 (0.81–1.04) | 0.161 | 13.37 | 0.270 | 0.845 | 0.340 |
Se meta-analysis | SARS-CoV-2 infection | 2 | 1.03 (0.95–1.11) | 0.506 | 1.68 | 0.195 | NA 2 | NA 2 |
Se meta-analysis | Hospitalized (ver. non-hospitalized) | 2 | 0.91 (0.75–1.11) | 0.347 | 0.58 | 0.445 | NA 2 | NA 2 |
Se meta-analysis | Hospitalized (ver. population) | 2 | 0.98 (0.87–1.10) | 0.715 | 0.28 | 0.599 | NA 2 | NA 2 |
Se meta-analysis | Very severe COVID-19 | 2 | 0.99 (0.83–1.17) | 0.864 | 0.22 | 0.638 | NA 2 | NA 2 |
Se ALSPAC subsignificant | SARS-CoV-2 infection | 12 | 0.99 (0.95–1.03) | 0.704 | 9.66 | 0.561 | 0.104 | 0.457 |
Se ALSPAC subsignificant | Hospitalized (ver. non-hospitalized) | 12 | 1.01 (0.88–1.16) | 0.844 | 12.15 | 0.353 | 0.675 | 0.439 |
Se ALSPAC subsignificant | Hospitalized (ver. population) | 12 | 1.03 (0.95–1.12) | 0.453 | 4.62 | 0.948 | 0.262 | 0.522 |
Se ALSPAC subsignificant | Very severe COVID-19 | 12 | 1.06 (0.94–1.19) | 0.369 | 6.77 | 0.817 | 0.278 | 0.642 |
Se QIMR subsignificant | SARS-CoV-2 infection | 15 | 1.00 (0.97–1.03) | 0.974 | 9.35 | 0.808 | 0.973 | 0.392 |
Se QIMR subsignificant | Hospitalized (ver. non-hospitalized) | 15 | 1.04 (0.94–1.16) | 0.412 | 17.82 | 0.215 | 0.050 | 0.352 |
Se QIMR subsignificant | Hospitalized (ver. population) | 15 | 1.06 (1.00–1.12) | 0.033 | 13.47 | 0.490 | 0.212 | 0.363 |
Se QIMR subsignificant | Very severe COVID-19 | 15 | 1.07 (0.99–1.16) | 0.069 | 11.77 | 0.624 | 0.679 | 0.371 |
Cu | SARS-CoV-2 infection | 2 | 1.07 (1.00–1.14) | 0.057 | 0.66 | 0.415 | NA 2 | NA 2 |
Cu | Hospitalized (ver. non-hospitalized) | 2 | 0.98 (0.79–1.21) | 0.842 | 0.00 | 0.984 | NA 2 | NA 2 |
Cu | Hospitalized (ver. population) | 2 | 1.07 (0.88–1.29) | 0.493 | 2.24 | 0.135 | NA 2 | NA 2 |
Cu | Very severe COVID-19 | 2 | 1.13 (0.82–1.55) | 0.467 | 2.84 | 0.092 | NA 2 | NA 2 |
Cu subsignificant | SARS-CoV-2 infection | 7 | 1.01 (0.96–1.07) | 0.662 | 11.30 | 0.080 | 0.022 | 0.227 |
Cu subsignificant | Hospitalized (ver. non-hospitalized) | 7 | 0.98 (0.86–1.12) | 0.792 | 1.39 | 0.967 | 0.006 | 0.882 |
Cu subsignificant | Hospitalized (ver. population) | 7 | 0.99 (0.91–1.08) | 0.816 | 5.09 | 0.532 | 0.018 | 0.493 |
Cu subsignificant | Very severe COVID-19 | 7 | 0.94 (0.83–1.07) | 0.326 | 3.87 | 0.694 | 0.017 | 0.672 |
vit. K1 subsignificant | SARS-CoV-2 infection | 3 | 0.99 (0.93–1.05) | 0.677 | 0.95 | 0.621 | 0.507 | 0.000 |
vit. K1 subsignificant | Hospitalized (ver. non-hospitalized) | 3 | 1.06 (0.88–1.28) | 0.565 | 0.50 | 0.779 | 0.697 | 0.000 |
vit. K1 subsignificant | Hospitalized (ver. population) | 3 | 0.98 (0.87–1.09) | 0.662 | 0.62 | 0.732 | 0.593 | 0.000 |
vit. K1 subsignificant | Very severe COVID-19 | 3 | 0.93 (0.72–1.19) | 0.546 | 4.42 | 0.110 | 0.349 | 0.084 |
1—Nominal p-value, 2—Insufficient number of SNPs for MR-Egger analysis.